Coronaridine
Clinical data | |
---|---|
ATC code |
|
Identifiers | |
IUPAC name
| |
CAS Number | |
PubChem CID | |
ChemSpider | |
ChEBI | |
CompTox Dashboard (EPA) | |
ECHA InfoCard | 100.006.727 |
Chemical and physical data | |
Formula | C21H26N2O2 |
Molar mass | 338.451 g·mol−1 |
3D model (JSmol) | |
SMILES
| |
InChI
|
Coronaridine, also known as 18-carbomethoxyibogamine, is an alkaloid found in Tabernanthe iboga and related species, including Tabernaemontana divaricata for which (under the now obsolete synonym Ervatamia coronaria) it was named.[1]
Like ibogaine, (R)-coronaridine and (S)-coronaridine can decrease intake of cocaine and morphine intake in animals[2] and it may have muscle relaxant and hypotensive activity.[3]
Chemistry
Congeners
Coronaridine congers are important in drug discovery and development due to multiple actions on different targets. They have ability to inhibit Cav2.2 channel,[4] modulate and inhibit subunits of nAChr selectively such as α9α10,[4] α3β4[5][6] and potentiate GABAA activity.[7]
Pharmacology
Coronaridine has been reported to bind to an assortment of molecular sites, including: μ-opioid (Ki = 2.0 μM), δ-opioid (Ki = 8.1 μM), and κ-opioid receptors (Ki = 4.3 μM), NMDA receptor (Ki = 6.24 μM) (as an antagonist),[8] and nAChRs (as an antagonist).[9] It has also been found to inhibit the enzyme acetylcholinesterase, act as a voltage-gated sodium channel blocker,[10] and displays estrogenic activity in rodents.[8][9] In contrast to ibogaine and other iboga alkaloids, coronaridine does not bind to either the σ1 or σ2 receptor.[10]
Sources
Family | Plants |
---|---|
Apocynaceae | T. catharinensis, T. ternifolia, T. pandacaqui, T. heyneana, T. litoralis, T. divaricata, T. penduliflora.[11] |
See also
- Dregamine
- Ibogaine
- Ibogamine
- Tabernanthine
- Voacangine
References
- ↑ Delorenzi JC, Freire-de-Lima L, Gattass CR, et al. (July 2002). "In vitro activities of iboga alkaloid congeners coronaridine and 18-methoxycoronaridine against Leishmania amazonensis". Antimicrobial Agents and Chemotherapy. 46 (7): 2111–5. doi:10.1128/aac.46.7.2111-2115.2002. PMC 127312. PMID 12069962.
- ↑ Spinella, Marcello (2001). The Psychopharmacology of Herbal Medicine: Plant Drugs that Alter Mind, Brain, and Behavior. The MIT Press; Illustrated edition. ISBN 978-0262692656.
- ↑ Perera, Premila; Kanjanapothy, Duangta; Sandberg, Finn; Verpoorte, Robert (1985). "Muscle relaxant activity and hypotensive activity of some tabernaemontana alkaloids". Journal of Ethnopharmacology. 13 (2): 165–173. doi:10.1016/0378-8741(85)90004-2. PMID 4021514.
- 1 2 Arias HR, Tae HS, Micheli L, Yousuf A, Ghelardini C, Adams DJ, Di Cesare Mannelli L (September 2020). "Coronaridine congeners decrease neuropathic pain in mice and inhibit α9α10 nicotinic acetylcholine receptors and CaV2.2 channels". Neuropharmacology. 175: 108194. doi:10.1016/j.neuropharm.2020.108194. hdl:2158/1213504. PMID 32540451. S2CID 219705597.
- ↑ Arias HR, Targowska-Duda KM, Feuerbach D, Jozwiak K (August 2015). "Coronaridine congeners inhibit human α3β4 nicotinic acetylcholine receptors by interacting with luminal and non-luminal sites". The International Journal of Biochemistry & Cell Biology. 65: 81–90. doi:10.1016/j.biocel.2015.05.015. PMID 26022277.
- ↑ Arias HR, Lykhmus O, Uspenska K, Skok M (March 2018). "Coronaridine congeners modulate mitochondrial α3β4* nicotinic acetylcholine receptors with different potency and through distinct intra-mitochondrial pathways". Neurochemistry International. 114: 26–32. doi:10.1016/j.neuint.2017.12.008. PMID 29277577. S2CID 3675707.
- ↑ Arias HR, Do Rego JL, Do Rego JC, Chen Z, Anouar Y, Scholze P, Gonzales EB, Huang R, Chagraoui A (July 2020). "Coronaridine congeners potentiate GABAA receptors and induce sedative activity in mice in a benzodiazepine-insensitive manner". Progress in Neuro-psychopharmacology & Biological Psychiatry. 101: 109930. doi:10.1016/j.pnpbp.2020.109930. PMID 32194202. S2CID 212734631.
- 1 2 Christophe Wiart (16 December 2013). Lead Compounds from Medicinal Plants for the Treatment of Neurodegenerative Diseases. Academic Press. pp. 67–69, 73. ISBN 978-0-12-398383-1.
- 1 2 Gideon Polya (15 May 2003). Biochemical Targets of Plant Bioactive Compounds: A Pharmacological Reference Guide to Sites of Action and Biological Effects. CRC Press. pp. 203–. ISBN 978-0-203-01371-7.
- 1 2 Chemistry and Biology. Academic Press. 21 September 1998. pp. 222–. ISBN 978-0-08-086576-8.
- ↑ European Bioinformatics Institute